New Softgel Technologies
Catalent Pharma Solutions recently launched several new softgel product developments, all of which solve a delivery problem, while offering IP advantages to drug manufacturers.
New Softgel Technologies
Catalent Pharma Solutions recently launched several new softgel product developments, all of which solve a delivery problem, while offering IP advantages to drug manufacturers.
In 2014 Catalent will celebrate 80 years of softgel manufacturing and the company has recently launched several new softgel product developments, all of which solve a delivery problem, while offering IP advantages to drug manufacturers.
OptiGel Micro™, designed for prescription drug products, can accommodate a wide range of fill formulations and be sized from 1mm to 7mm in diameter, smaller than conventional capsules made using a rotary die.
Benefits include easier swallowing and capsule size can make compliance and adherence less daunting.
OptiGel Lock™, is designed to prevent the abuse of prescription pain medications, and the deliberate misuse of consumer pseudoephedrine products. Softgels cannot easily be ignited, ground or crushed into powders. For example, it can limit the amount of pseudoephedrine that can be extracted to use as a raw material for the manufacture of crystal meth.
OptiGel Bio™ enables macromolecules to be delivered orally and overcome permeability and stability challenges in a more easily administered form than intravenous injection.
OptiGel Bio may improve the permeability of large molecule APIs, while also enabling targeted delivery to be achieved via an enteric coating. This protective coating can also limit degradation of the API in the stomach. Patient advantages include fewer physician visits and less painful administration.
Company name: Catalent Pharma Solutions
Website: www.catalent.com
E-mail:
[email protected]
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
